Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis as a Panelist at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)
Anne Altmeyer, Executive Director, Business Development & Licensing, Oncology, at Novartis is a Panelist in “Panel Discussion: Innovative Partnering & Licensing Strategies” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
Casey C. Kopczynski, Chief Scientific Officer at Aerie Pharmaceuticals Will Give a Presentation at the 4th Ocular Diseases and Drug Discovery Conference (February 27-28, 2012 in Las Vegas, NV)
Casey C. Kopczynski, Chief Scientific Officer at Aerie Pharmaceuticals will give a presentation on “Rho Kinase Inhibitors for Glaucoma” at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.
David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos Will Give a Joint Featured Presentation at the 4th Ocular Diseases and Drug Discovery Conference
David Woodward, Senior Director of Biological Sciences at Allergan and Barbara Wirostko, Chief Medical Officer at Altheos will give a joint featured presentation entitled “Critical Success Factors in Approving Ophthalmic Drugs: Prostaglandins for Glaucoma/OHT as a Case Study: What Next?” at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.
John C. Lin, Vice President of Experimental Medicine at Pfizer Will Give a Featured Presentation at the 4th Ocular Diseases and Drug Discovery Conference (February 27-28, 2012 in Las Vegas, NV)
John C. Lin, Vice President of Experimental Medicine at Pfizer will give a featured presentation on “Anti-amyloid Beta in Age-related Macular Degeneration” at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.
Denis Patrick at Pfizer to Present at Oncology Partnering Conference - Oct 27-28, 2012, Las Vegas
Denis Patrick, Senior Director & Head, External R&D Innovation, Oncology Research Unit at Pfizer to give a Featured Presentation on “Antibody Drug Conjugation Technology: Past, Present and Future” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
Iain Dukes, VP, R&D at Amgen to Speak at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas
Iain Dukes, Vice President, External R&D at Amgen is a Panelist in “Panel Discussion: Trends in Oncology Drug Development” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
John Herrmann at Eli Lilly to Present at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas
John Herrmann, Senior Director, Global External Research & Development, Oncology at Eli Lilly to give a Featured Presentation on “Partnering with Lilly Oncology: Bring Proof-of-Relevance or Go Lean-to-POC” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
Claude Gimmi at Boehringer to Present at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas
Claude Gimmi, Global Head, Business development and Licensing Oncology, Therapeutic Alliances and Strategic Partnerships at Boehringer-Ingelheim to give a Featured Presentation on “Sincerely, Yours – Partnering with Boehringer Ingelheim in Oncology” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.
Henry (Hank) F. Edelhauser, Professor of Research (Basic Science) Section at Emory Will Give a Keynote Presentation at the 4th Ocular Diseases and Drug Discovery Conference (February 27-28, 2012 in Las Vegas, NV)
Henry (Hank) F. Edelhauser, Professor of Research (Basic Science) Section at Emory will give a Keynote presentation on “Preservative Free or BAK Free Formulations, That is the Question?” at the 4th Ocular Diseases and Drug Discovery Conference taking place on February 27-28, 2012 in Las Vegas, NV.
Pharmaceutical Industry Decision-makers, Scientists, Researchers, Technology Developers and Investors Will Gather in One Location at GTC’s Biomarker Summit 2012, March 15-16 in San Diego, CA
Creating a unique gathering place for the pharmaceutical industry, GTC is pleased to announce the Biomarker Summit 2012 to be held on March 15-16, 2012 at the Paradise Point Resort in San Diego. The Summit will be the first of its kind to bring together biomarker development, diagnostics, oncology and business interests.